Table 1.
Disease Characteristics and Biomarker Results for Subjects With Suspected Inflammatory Bowel Disease
| Controls (n = 72) | UC/IBD-U (n = 16) | Crohn’s (n = 60) | |
|---|---|---|---|
| Median age at endoscopy (range), y | 15(6–20) | 15(4–18) | 14(4–21) |
| Female, % | 44 (61%) | 10 (63%) | 20 (33%)a |
| White race, % | 63 (88%) | 16 (100%) | 52 (87%) |
| Crohn’s location | |||
| Ileal only (L1) | 9 | ||
| Colon only (L2) | 12 | ||
| Ileocolonic (L3) | 39 | ||
| Proximal to ligament of Treitz (L4a) | 24 | ||
| Crohn’s behavior | |||
| Inflammatory (B1) | 48 | ||
| Stricturing (B2) | 6 | ||
| Penetrating (B3) | 6 | ||
| Stricturing/penetrating (B2B3) | 0 | ||
| Perianal | 7 | ||
| SES-CD, median (range) | NA | NA | 13(3–31) |
| Biomarker at endoscopy | |||
| Neutrophil CD64 index, median (range) | 0.65 (0.3–1.6) | 1.1 (0.4–2.6)b | 1.7 (0.4–4.4)c |
| Soluble CD64, median (range), ng/mL | 29 (12–73) | 43 (34–131)d | 73 (27–174)c |
| Neutrophil CD64 activity index, median (range) | 4 (2.1–14.6) | 6 (3.9–7.5)e | 7.6 (2.2–30.4)c |
| CRP, median (range), mg/dL | 0.28 (0.28–4.5) | 0.28 (0.28–5.7) | 2 (0.28–14)c |
| Fecal calprotectin, median (range), μg/g | 76 (15–1066) | 1173 (65–1251)b | 863 (55–1251)c |
Lower limit CRP detection for clinical laboratory is <0.29 mg/dL, input 0.28 mg/dL. Biomarkers were compared for (a) controls vs Crohn’s and (b) controls vs UC/IBD-U.
a P < 0.01 Crohn’s vs controls.
b P < 0.001 UC vs controls.
c P < 0.001 Crohn’s vs controls.
d P < 0.01 UC vs controls.
e P < 0.05 UC vs controls.
SES-CD = Simple Endoscopic Score–Crohn’s disease.